The search for new treatments to combat malaria has been hampered by the lack of validated targets on the parasite that causes the disease. In work recently published in PNAS, a team from the Drug Discovery Unit at the University of Dundee present a new compound that is a selective inhibitor of the lysyl-tRNA synthetase enzyme in the parasites that cause malaria and cryptosporidiosis. Their work validates lysyl-tRNA synthetase as a drug target in these organisms and offers a strong lead for future drug discovery.
Click here for original story, Macromolecular crystallography shines a light on a new way to target the malaria parasite
Source: Phys.org